Wow_老虎社区_美港股上老虎

Vic12
2021-11-25

Wow

Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial

Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evalu

Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":874297188,"tweetId":"874297188","gmtCreate":1637782136457,"gmtModify":1637782136542,"author":{"id":3554281144270981,"idStr":"3554281144270981","authorId":3554281144270981,"authorIdStr":"3554281144270981","name":"Vic12","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/874297188","repostId":1151417653,"repostType":4,"repost":{"id":"1151417653","kind":"news","pubTimestamp":1637765751,"share":"https://www.laohu8.com/m/news/1151417653?lang=&edition=full","pubTime":"2021-11-24 22:55","market":"us","language":"en","title":"Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1151417653","media":"Benzinga","summary":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evalu","content":"<p><b>Gilead Sciences Inc</b>&nbsp;and&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;have&nbsp;temporarily paused enrollment&nbsp;in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.</p>\n<ul>\n <li>The temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after&nbsp;Merck decided to stop the MK-8507 combination HIV trial.</li>\n <li>Participants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.</li>\n <li>The Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.</li>\n <li>Lenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.</li>\n <li>Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","MRK":"默沙东"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151417653","content_text":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after Merck decided to stop the MK-8507 combination HIV trial.\nParticipants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.\nThe Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.\nLenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.\nIslatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.","news_type":1},"isVote":1,"tweetType":1,"viewCount":460,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial

评论（1）

热议股票